Vitruvian BioMedical, Inc.


Phone: 1-800-580-5020

  Alzheimer's DNA Aβ42 Vaccine | Alzheimer's Diagnostics 

Alzheimer's disease vaccine & Diagnostics

The DNA Aβ42 Vaccine is a patented technology for the prevention of  Alzheimer’s Disease[i]. The vaccine is a gene-based (DNA) amyloid beta 42 (Aβ42) vaccine in preclinical development for prevention of Alzheimer's disease (AD). Unlike a traditional vaccine for AD, the DNA vaccine does not contain amyloid beta itself but instead contains a piece of the gene coding for the amyloid beta protein[ii]. Once in the body, the vaccine stimulates an immune response  resulting in antibodies that bind to and significantly reduce amyloid beta. Amyloid beta accumulation in the brain has been shown to be one of the earliest steps in the development of Alzheimer Disease. Research has shown that a unique property of this vaccine is that it does not elicit an inflammatory response in the brain[ii,iii] which is critical for a successful vaccine. The vaccine was developed at University of Texas Southwestern Medical School and a US patent 7,479.550 B2 issued in 2009[i].    

The ALZHEIMER'S DIAGNOSTIC Technology is a Biomarker-Based Blood Test for Alzheimer's Disease. Biomarkers are unique molecules which permit identification of different diseases. This proprietary Alzheimer's Disease Biomarker serves as the basis for a Diagnostic Blood Test which could help identify candidates for the Alzheimer's Disease Vaccine.

In the United States alone, Alzheimer's disease currently affects 5.4 million people and their families. It is the most common form of dementia and the fifth leading cause of death for individuals 65 years and older. The Alzheimer's Association estimates that the disease results in $200 billion dollars of healthcare costs in the United States each year[iv].
 

Future Technology

In keeping with its mission of “Advanced Personalized Medicine”, our Management Team continues to evaluate  technologies that have market potential for growth and garners a reputation for successful commercialization of  safe and cost effective diagnostic and therapeutic products in the United States and worldwide. 

________________________________

[i]   U.S. Patent 7,479,550 B2

[ii]  J. Neurol. Sci. 260 (2007): 204-213

[iii] Vaccine 28 (2010): 5280-5287

[iv] “2012 Alzheimer's Disease Facts and Figures” Alzheimer's Association: http://www.alz.org/alzheimers_disease_facts_and_figures.asp

[v] Journal of the National Cancer Institute. (2011). Cancer Care Costs in the United States: Projections 2010-2020. doi: 10.1093/jnci/djr009